WEbCAST series - are you taking an integrated approach?

Any prescription medicine has the potential to be abused, however, drug products affecting the Central Nervous System (CNS) and those able to produce rewarding psychoactive effects are considered to be at greater risk of being misused. As a result, preclinical evaluations of the abuse potential of new drugs affecting the CNS are an integral component of new drug applications (NDA).

In this two-part webcast series independent Consultant, Mary Jeanne Kallman and Evotec Research Leader, Abuse Liability, Michela Tessari will present practical and methodological approaches to preclinical drug abuse liability assessment of novel CNS-active candidates in light of International Regulatory Agencies' recommendations.

Experts will discuss a number of critical parameters that should be carefully considered when designing animal behavioural studies to investigate the abuse potential of novel compounds. 

Part one | Abuse Liability Assessment of new drugs from candidate selection to New Drug Application

Part two | Abuse Liability Assessment of new drugs: core preclinical studies to address regulatory requirements

Fill in the form below to listen to the webcasts now!


About the speakers


Mary Jeanne Kallman 2Mary Jeanne Kallman PhD, DSP

Mary Jeanne was an Associate Professor and Director of the PhD Experimental Graduate Program at the University of Mississippi for 9 years. She worked for Lilly Research Labs for 17 years as the Group Leader for Safety Pharmacology in their Toxicology Group where she provided drug develop solutions in rodents, primates and dogs as needed.  She also worked for Covance Laboratories, a large CRO, as the Global Director of Neuroscience and she is currently managing a consulting business which provides input on CNS issue resolution and abuse liability strategies for drugs in development.
  • Mary Jeanne earned a PhD from the University of Georgia in Neuroscience and completed a postdoctoral fellowship in pharmacology and toxicology at Virginia Commonwealth University
  • Mary Jeanne holds diplomate status in the Safety Pharmacology Society and she has held several professional leadership positions including President of the Safety Pharmacology Society, Leader of the Scientific Liaison Coalition (SLC) of SOT, and co-leader of the Cross Company Abuse Liability Council (CCALC)

Mary Jeanne frequently publishes scientific papers, book chapters, and presents on various CNS issues. She received EPA and NIH funding for her research and support of her academic laboratory.


Michela TessariMichela Tessari | Research Leader, Abuse Liability, Global Preclinical Development, Evotec

Michela is an experienced pharmaceutical scientist with a strong expertise in the drug dependence field. She has contributed to many programmes as an in-vivo pharmacologist responsible for the behavioural assays (pharmacodynamic and disease) in rodents with relevance for multiple CNS disease areas. She has led the implementation of GLP regulations in the conduction of behavioural studies for the investigation of abuse potential.

  • Michela has a degree in Biology from the University of Padua (Italy) and a postgraduate master degree in Experimental Pharmacology from the University of Milan (Italy)
  • She is currently responsible for abuse liability assessment studies within Preclinical Development at Evotec

Michela is a member of the Safety Pharmacology Society.

View the webcasts